Research on the Accurate Diagnosis of Urinary Tract Tumors and the Development of Kits
NCT ID: NCT06193941
Last Updated: 2024-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
400 participants
OBSERVATIONAL
2023-06-01
2023-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Urine VOC Investigation in Bladder Cancer Diagnosis
NCT05671289
Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder
NCT02745301
The Research Value of Multi-omics and Multi-modal Information in the Diagnosis and Treatment of Urinary System Tumors
NCT06490211
Development of a Non-Invasive DNA Methylation-Based Assay System for the Risk Assessment of Urothelial Carcinoma
NCT00867620
Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue
NCT02379429
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Case group (bladder cancer)
Urine exosomes were enriched for RT-qPCR within 4 hours after samples were collected.
RT-qPCR
RT-qPCR
Control group (benigh)
Urine exosomes were enriched for RT-qPCR within 4 hours after samples were collected.
RT-qPCR
RT-qPCR
Healthy people group
Urine exosomes were enriched for RT-qPCR within 4 hours after samples were collected.
RT-qPCR
RT-qPCR
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RT-qPCR
RT-qPCR
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Preoperative patients are preliminarily evaluated as bladder tumors by cystoscopy, FISH, cytology, or imaging.
Exclusion Criteria
2. Post-operative or after anti-tumor treatment such as chemotherapy or immunotherapy
3. History of other malignant tumors
4. Specimens with hemolytic conditions;
5. Patients with incomplete, undocumented, and uncooperative data.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhongnan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fubing Wang, Doctor
Role: PRINCIPAL_INVESTIGATOR
Wuhan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
W20231218
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.